Search results
Results from the WOW.Com Content Network
Due to myostatin's effect as a negative regulator of bone, its inhibition has also been considered for orthopedic diseases such as rheumatoid arthritis. [15] Myostatin inhibitors were generally able to increase lean body mass and reduce body fat in people with sarcopenia, but the extent to which this translated into functional improvements ...
Myostatin is a myokine that is produced and released by myocytes and acts on muscle cells to inhibit muscle growth. [7] Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family. [8] [9] Myostatin is assembled and produced in skeletal muscle before it is released into the blood stream. [10]
Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. [ 3 ] Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin ...
Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy.It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin.
Pages in category "Myostatin inhibitors" The following 7 pages are in this category, out of 7 total. This list may not reflect recent changes. A. Apitegromab; B.
Myostatin-related muscle hypertrophy is a rare genetic condition characterized by reduced body fat and increased skeletal muscle size. [1] Affected individuals have up to twice the usual amount of muscle mass in their bodies, but increases in muscle strength are not usually congruent. [ 2 ]
In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. [6] In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. [ 7 ]
Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.